Retreatment of HCV Genotype 1 DAA-failures with Ombitasvir/Paritaprevir/r, Dasabuvir, and Sofosbuvir—F Poordad et. al - Alan Franciscus


Abstract:  Retreatment of HCV G-1 DAA-failures with Ombitasvir/Paritaprevir/r, Dasabuvir, and Sofosbuvir—F Poordad et. al       
Source:  The Liver Conference – Late Breaker – 20 

Results and Conclusions
The investigators evaluated the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir plus sofosbuvir in direct-acting antiviral-experienced patients with HCV genotype 1 with and without cirrhosis.
One genotype 1a patient without cirrhosis had detectable RNA (viral load) at week 4—their treatment duration was extended to 24 weeks.  There was one treatment discontinuation, but it was not related to the study drug and the patients achieved a cure.  The most common side effects were headache, fatigue, diarrhea and insomnia.

The Bottom Line
A cure rate of 92% to 100% is very encouraging in this difficult to treat population.    

Editorial Comment
This combination of drugs to hit treatment related RAVs hard is a good strategy.   However, more clinical trials are needed to find out if this approach will work in other HCV treatment RAVs.

Labels: , , , ,